Navigation Links
Lifesaving HIV treatment could reach millions more people following landmark study

Millions more people could get access to life-saving HIV drug therapy, following a landmark study led by Australian researchers based at the Kirby Institute at the University of New South Wales (UNSW).

The researchers have found a lower daily dose of an important HIV drug therapy is safe and as effective in suppressing the virus as the standard recommended dose.

The findings have been presented at the International AIDS Society Conference in Kuala Lumpur, Malaysia.

"This has the potential to affect the treatment of millions of HIV positive people," says UNSW Professor Sean Emery, the protocol chairperson of the study, known as ENCORE1 and Head of the Therapeutic and Vaccine Research Program at the Kirby Institute.

"A reduced daily dose should translate into a lower cost of treatment and permit more effective and efficient use of health care resources. Essentially, more people could receive this life-saving treatment for the same amount of funding."

HIV-positive people from 13 countries in Africa, Asia, Australia, Europe and Latin America took part in the trial. Half these people took two-thirds of the current standard daily dose of the antiretroviral (ART) efavirenz, a commonly used treatment for HIV; the other half took the standard daily dose. The 630 participants were observed regularly for a year. The results indicate that a reduction in daily dose of one third is both safe and effective compared to the higher dose currently recommended for people with HIV infection.


Contact: Laurie Legere
University of New South Wales

Page: 1

Related biology news :

1. Continued research needed on treatment for women with lung cancer who are never smokers
2. Artificial sweetener a potential treatment for Parkinsons disease
3. Posttraumatic stress disorder treatment: Genetic predictor of response to exposure therapy
4. Scientists identify potential drug target for treatment-resistant anemias
5. Neurochemical traffic signals may open new avenues for the treatment of schizophrenia
6. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
7. Engineered stem cell advance points toward treatment for ALS
8. Using big data to identify prostate cancers and best treatments
9. First successful treatment of pediatric cerebral palsy with autologous cord blood
10. Cutting-edge bacteria research leads to more effective treatment of complex infections
11. Study identifies possible new acute leukemia marker, treatment target
Post Your Comments:
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology: